Novigenix S.A.

https://www.novigenix.com

LinkedIn: https://www.linkedin.com/company/novigenix

Novigenix is a precision medicine biotech providing a new understanding of the human host response to cancer and its response to therapy. The Company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients, leading to significant improvement in healthcare. Novigenix’s unique Immuno-Transcriptomic platform enables an accelerated identification of disease specific mRNA signatures of immune cells, which combined with machine learning and predictive algorithms provide new insights into onset and progression of disease. For more information visit www.novigenix.com About LITOseek The Liquid Immuno-Transcriptomic Sequencing Platform of Novigenix, LITOseek, analyzes the gene expression modifications (mRNA signatures) induced by the host immune response to various triggers, such as onset of cancer. Disease specific algorithms are developed through application of Artificial Intelligence on patient mRNA signatures in combination with clinical and medical parameters. The LITOseek platform has been designed and optimized for development of precision oncology solutions based on the human Immuno-Transcriptome, with continuous improvement of predictive and adaptive algorithms. *

	Start	2014-01-01 established
	Industry	LITOseek™ platform (Blood Immuno-Transcriptomic Sequence platform)
	Industry 2	personalised medicine / precision medicine

	Region	Lausanne VD
	Country	Switzerland
	Street	3B Route de la Corniche Biopôle IV
	City	1066 Epalinges VD
	Tel	+41-21-552-0730
		Address record changed: 2022-11-23

Basic data	Employees	n. a.

		* Document for »About Section«: Novigenix S.A.. (11/16/22). "Press Release: Novigenix Announces First Closing of Its $20M Series B". Lausanne.

		Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Novigenix S.A.

[1] Novigenix S.A.. (9/19/19). "Press Release: Novigenix and BioLizard Sign Collaboration Agreement for Development of NGS Based Diagnostic Algorithm". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)